Cargando…

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice

BACKGROUND: Enterovirus 71 (EV71) is the major causative agent of hand, foot, and mouth disease (HFMD). Three inactivated EV71 whole-virus vaccines of different strains developed by different manufacturers in mainland China have recently entered clinical trials. Although several studies on these vac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Qunying, Dong, Chenghong, Li, Xiuling, Gao, Qiang, Guo, Zengbing, Yao, Xin, Wang, Yiping, Gao, Fan, Li, Fengxiang, Xu, Miao, Yin, Weidong, Li, Qihan, Shen, Xinliang, Liang, Zhenglun, Wang, Junzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460965/ https://www.ncbi.nlm.nih.gov/pubmed/23029378 http://dx.doi.org/10.1371/journal.pone.0046043

Ejemplares similares

Study of the Integrated Immune Response Induced by an Inactivated EV71 Vaccine
por: Liu, Longding, et al.
Publicado: (2013)

EV71 vaccine, an invaluable gift for children
por: Liang, Zhenglun, et al.
Publicado: (2014)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches
por: Shao, Jie, et al.
Publicado: (2015)

Progress on the research and development of inactivated EV71 whole-virus vaccines
por: Liang, Zheng-Lun, et al.
Publicado: (2013)

Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
por: Liu, Pei, et al.
Publicado: (2021)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial
por: Li, Yan, et al.
Publicado: (2021)

The Cross-Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children
por: Mao, Qunying, et al.
Publicado: (2013)

Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC
por: Liang, Zhenglun, et al.
Publicado: (2014)

Induction of SOCS Expression by EV71 Infection Promotes EV71 Replication
por: Gao, Wenying, et al.
Publicado: (2020)

A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71
por: Wang, Xiangxi, et al.
Publicado: (2012)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations
por: Liu, Longding, et al.
Publicado: (2015)

Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems
por: Lin, Chih-Wei, et al.
Publicado: (2014)

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
por: Liao, Yun, et al.
Publicado: (2023)

Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71
por: Dang, Minghao, et al.
Publicado: (2014)

Analysis of Cross-Reactive Neutralizing Antibodies in Human HFMD Serum with an EV71 Pseudovirus-Based Assay
por: Zhang, Huafei, et al.
Publicado: (2014)

Development and Evaluation of a Pseudovirus-Luciferase Assay for Rapid and Quantitative Detection of Neutralizing Antibodies against Enterovirus 71
por: Wu, Xing, et al.
Publicado: (2013)

The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo
por: Ren, Peijun, et al.
Publicado: (2014)

COVID-19 vaccines: progress and understanding on quality control and evaluation
por: Mao, Qunying, et al.
Publicado: (2021)

Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection
por: Chang, Guo-hui, et al.
Publicado: (2010)

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
por: He, Qian, et al.
Publicado: (2022)

A cross-sectional seroepidemiology study of EV-D68 in China
por: Sun, Shiyang, et al.
Publicado: (2018)

Protective effect of enterovirus-71 (EV71) virus-like particle vaccine against lethal EV71 infection in a neonatal mouse model
por: CAO, LEI, et al.
Publicado: (2015)

EV71-infected CD14(+) cells modulate the immune activity of T lymphocytes in rhesus monkeys
por: Wang, Jingjing, et al.
Publicado: (2013)

Plant-Produced Anti-Enterovirus 71 (EV71) Monoclonal Antibody Efficiently Protects Mice Against EV71 Infection
por: Rattanapisit, Kaewta, et al.
Publicado: (2019)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Both ERK1 and ERK2 Are Required for Enterovirus 71 (EV71) Efficient Replication
por: Zhu, Meng, et al.
Publicado: (2015)

Production of EV71 vaccine candidates
por: Chong, Pele, et al.
Publicado: (2012)

Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial
por: Tong, Yeqing, et al.
Publicado: (2022)

Inhibition of Enterovirus 71 (EV-71) Infections by a Novel Antiviral Peptide Derived from EV-71 Capsid Protein VP1
por: Tan, Chee Wah, et al.
Publicado: (2012)

Flavonoids as Antiviral Agents for Enterovirus A71 (EV-A71)
por: Lalani, Salima, et al.
Publicado: (2020)

EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge
por: Wang, Xiaowen, et al.
Publicado: (2016)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
por: Zhang, Jialu, et al.
Publicado: (2021)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

DNA aptamer against EV-A71 VP1 protein: selection and application
por: Zou, Xinran, et al.
Publicado: (2021)

Phenotypic and Genotypic Characteristics of Novel Mouse Cell Line (NIH/3T3)-Adapted Human Enterovirus 71 Strains (EV71:TLLm and EV71:TLLmv)
por: Victorio, Carla Bianca Luena, et al.
Publicado: (2014)

Delivery of Human EV71 Receptors by Adeno-Associated Virus Increases EV71 Infection-Induced Local Inflammation in Adult Mice
por: Hsiao, Hung-Bo, et al.
Publicado: (2014)

The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus
por: Wu, Chia-Ying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_243mafjqhdqml93gq7u6i2anab